Lexicon Pharmaceuticals, Inc. (LXRX)

Last Closing Price: 0.67 (2025-06-13)

Company Description

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomictechnologies to accelerate large-scale analysis of mammalian gene function for drug discovery.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $31.08M
Net Income (Most Recent Fiscal Year) $-200.40M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 7.78
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 1.97
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -568.04%
Net Margin (Trailing 12 Months) -568.04%
Return on Equity (Trailing 12 Months) -103.16%
Return on Assets (Trailing 12 Months) -54.95%
Current Ratio (Most Recent Fiscal Quarter) 2.22
Quick Ratio (Most Recent Fiscal Quarter) 2.22
Debt to Common Equity (Most Recent Fiscal Quarter) 0.48
Inventory Turnover (Trailing 12 Months) 1.49
Book Value per Share (Most Recent Fiscal Quarter) $0.40
Earnings per Share (Most Recent Fiscal Quarter) $-0.07
Earnings per Share (Most Recent Fiscal Year) $-0.63
Diluted Earnings per Share (Trailing 12 Months) $-0.51
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 361.49M
Free Float 311.25M
Market Capitalization $242.74M
Average Volume (Last 20 Days) 3.64M
Beta (Past 60 Months) 1.00
Percentage Held By Insiders (Latest Annual Proxy Report) 13.90%
Percentage Held By Institutions (Latest 13F Reports) 74.70%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%